Valeant Pharmaceuticals Announces Planned Management Departure - 21 News Now, More Local News for Youngstown, Ohio -

Valeant Pharmaceuticals Announces Planned Management Departure

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Valeant Pharmaceuticals International, Inc.

LAVAL, Quebec, June 13, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE: VRX) (TSX: VRX) today announced that Ryan Weldon, Valeant's Executive Vice President and Company Group Chairman, will be leaving the Company following the divestiture of all rights to Restylane, Perlane, Emervel, Sculptra, and Dysport owned or held by Valeant to Nestlé S.A.  Nestle expects to complete its acquisition of Galderma S.A. in July and would expect to operate the acquired assets through Galderma. 

"The Board of Directors and I appreciate the significant contributions Ryan has made during his time with Valeant, especially his efforts through the Medicis integration and his tireless dedication with the aesthetic and dermatology communities," said J. Michael Pearson, chairman and chief executive officer.  "As a clear testament to the performance of Valeant's aesthetic commercial team, Galderma is in discussions with the injectable team to discuss long-term opportunities.  Although his leadership will be missed, the company has created and developed a strong management team and I am confident Ryan will assist us successfully through this transition period."

"The last six years at Valeant has been an extraordinary experience," said Ryan Weldon.  "It has been a privilege to work with Mike, my fellow Valeant employees, and the Board on this journey."

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology  and branded generics. More information about Valeant can be found at www.valeant.com.

Forward-looking Statements

This press release may contain forward-looking statements, including, but not limited to, statements regarding the long-term opportunities at Galderma for the aesthetics team. Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the company's most recent annual or quarterly report filed with the Securities and Exchange Commission ("SEC") and other risks and uncertainties detailed from time to time in the Company's filings with the SEC and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.

Contact Information:
Valeant Pharmaceuticals:
Investors:                                                                   
Laurie W. Little
Valeant Pharmaceuticals International, Inc.                                                       
949-461-6002                                                             
laurie.little@valeant.com                                           

Media:
Renee E. Soto/Meghan Gavigan
Sard Verbinnen & Co.
212-687-8080
rsoto@sardverb.com / mgavigan@sardverb.com

Valeant Pharmaceuticals International, Inc.

 Logo - http://photos.prnewswire.com/prnh/20101025/LA87217LOGO

©2012 PR Newswire. All Rights Reserved.

  • More From wfmj.comMore>>

  • Authorities recover man's body after boat sinks

    Authorities recover man's body after boat sinks

    Sunday, August 31 2014 8:23 PM EDT2014-09-01 00:23:38 GMT
    Authorities recovered the body of a 22-year-old man from a western Ohio lake after responding to a call about a sinking boat.More >>
    Authorities recovered the body of a 22-year-old man from a western Ohio lake after responding to a call about a sinking boat.
    More >>
  • Bad weather shuts down concerts, delays flights

    Bad weather shuts down concerts, delays flights

    Sunday, August 31 2014 8:12 PM EDT2014-09-01 00:12:58 GMT
    Severe thunderstorms across the Northeast have slowed operations at airports, wreaked havoc at outdoor sporting and musical events and sent people scurrying from a beach in New York after three men there were struck by lightning.More >>
    Severe thunderstorms across the Northeast have slowed operations at airports, wreaked havoc at outdoor sporting and musical events and sent people scurrying from a beach in New York after three men there were struck by lightning.
    More >>
  • University of Toledo forms water task force

    University of Toledo forms water task force

    Sunday, August 31 2014 1:26 PM EDT2014-08-31 17:26:31 GMT
    A university in northwestern Ohio says it's forming a group to help government leaders deal with the ongoing algae threat on Lake Erie.More >>
    A university in northwestern Ohio says it's forming a group to help government leaders deal with the ongoing algae threat on Lake Erie.
    More >>
Powered by WorldNow
All content © Copyright 2000 - 2014 Worldnow and WFMJ. All Rights Reserved. For more information on this site, please read our Privacy Policy and Terms